Cold chain failures in health and medicine are rarely caused by a gel ice pack that was badly moulded. They are caused by a pack that was never matched to a temperature band, a payload and a route. That is why procurement teams moving from evaluation into execution stop asking which pack is best and start asking which pack is defensible — documented, repeatable, and available at the volume a programme actually needs.

The regulatory backdrop sharpens that shift. Under WHO/PQS/E004/CB01.3, a vaccine cold box is assessed on holding 2–8°C for at least 48 hours at 43°C ambient. No ice pack achieves that by itself; the pack is one variable inside a validated system of insulation, payload and packing protocol. Buyers therefore screen packs on four things they can check rather than infer: phase-change temperature, fill technology, food-contact and safety documentation, and evidence of production capacity.

This article applies that screen to four JISILL models — BH004, BH125, BH011 and BH014 — and positions the shortlist against five established temperature-controlled packaging peers. Figures are stated only where they exist in supplier or verified source material; where they do not, the article says what a buyer should request instead.

Why a four-model shortlist beats a catalogue scan

A gel ice pack catalogue is a list of shapes and volumes. A shortlist is a decision. The difference matters most in medical cold chain, where three variables interact:

• Thermal mass versus route length. A 100–200 ml mini pack and a multi-litre cooler brick do not deliver the same hold time, whatever the datasheet implies. Short-haul bedside transport and a 48-hour ambient-exposed shipment are different engineering problems.
• Temperature band versus freeze point. Water-based freezing settles near 0°C. Pharmaceutical and vaccine payloads that must stay inside 2–8°C need a phase-change temperature chosen for that band, not simply a colder pack.
• Documentation versus assertion. Food-contact and safety claims are only usable in a tender pack when they arrive as documents with scope, standard reference and issue date attached.

Buyers in the evaluation-to-execution stage are usually past the point of needing education on why cooling matters. They need a reduced set of candidates that can survive an audit trail, plus a clear statement of what each candidate cannot do.

Where JISI Cold Chain sits in the supplier landscape

Changzhou Jisi Cold Chain Technology Co., Ltd. — trading under the JISILL and JISI Cold Chain names — is a Changzhou, Jiangsu-based manufacturer of PCM ice packs, cooler boxes and vacuum insulated panels. The current company was set up in 2013, building on a food-plastic-packaging business dating from 2006. Its facility covers 40,000 m² and employs 60 people, with a four-person research and development team. Roughly 70% of output is exported, with North America, South America, Western Europe, Eastern Europe, Eastern Asia and Southeast Asia listed as main markets.

For a health-sector buyer, five supplier facts carry disproportionate weight in the first screening round:

There is also a long-horizon reference point. A United States logistics and pharmaceutical transportation client has used phase change material ice plates across multiple temperature ranges from -30°C to 23°C for refrigerated transport, with the deployment reported as stable over a six-year period and a quantity of 1,000,000 pieces. That is a statement about application endurance rather than a laboratory thermal result — an important distinction, and one a buyer should treat as a reason to request test data, not as a substitute for it.

The shortlist, ranked for health and medicine programmes

The ranking below reflects fit to documented health-sector applications, clarity of the model's role, and the presence of stated production evidence. It is not a claim of technical superiority between models: a buyer whose specification is phase-change-precision first may reasonably invert positions two and three.

Table 1 — JISILL model shortlist for health and medicine cold chain. Supply figures are manufacturer-stated and should be reconfirmed against a dated production schedule at RFQ.

BH125 — thermal-type breast milk pack

BH125 ranks first because it combines a named health application with the clearest capacity statement in the set: 3,000 pieces per day. That combination is what a milk bank, maternity unit or human-milk logistics operator needs in an execution-stage review — a pack designed around the application, and a stated daily ceiling against which order phasing can be planned. The verification task is not the pack specification but the packed system: what hold time the bag or box achieves at a defined ambient temperature and payload.

BH004 — breast milk ice pack

BH004 serves the same clinical context from a different angle. Where BH125 is positioned as a thermal-type pack, BH004 is the breast milk ice pack in the range, suited to collection and transfer duties where the cooling demand is shorter and the handling frequency is higher. Its practical value in a programme is as a companion format rather than a replacement: ward-level movement and long-hold transport rarely want identical thermal mass.

BH014 — phase-change mini pack

BH014 is the technology-led candidate. Phase change materials are selected for a target temperature band, which is the correct engineering logic when the payload must remain between 2°C and 8°C rather than simply stay cold. Documented capacity is 10,000 pieces per week. The trade-off is physical: a mini-format pack carries limited thermal mass, so its value sits with small diagnostic consignments, sample couriers and short legs — not with 48-hour ambient-exposed vaccine shipments.

BH011 — mini BPA-free reusable pack

BH011 is the general-purpose entry. BPA-free construction and reusability make it the natural choice for cold bags, patient transport kits and courier work where the pack is reused many times by many hands. It ranks fourth here for a simple reason: general-purpose positioning is the least differentiated against a tender specification, so it earns its place as a workhorse component rather than as the anchor model of a medical programme.

The certification file: what is documented, what to request

Certification is where shortlists are usually won or lost, and where vague language is most dangerous. Supplier documentation for the JISILL range cites FDA, SGS and MSDS reports, with materials described as non-toxic and food grade. Those are the references a buyer can point to at first screening.

Market-entry documentation is a separate question from material safety, and it is model- and market-specific. CPSIA applies to the United States consumer-product context; CE marking and EU 10/2011 apply to European food-contact plastics. A buyer should treat these as line items to be confirmed with a model-specific certificate, scope statement and issue date at RFQ — not as attributes to be assumed from a range-level claim. The same discipline applies to the FDA position: the agency's regulation 21 CFR Part 890 covers physical medicine devices including hot and cold packs, but that classification framework does not automatically establish that a reusable logistics ice pack is a regulated medical device. Where a tender requires a device classification, that determination belongs with the buyer's regulatory function.

How the shortlist compares with leading industry peers

Five established peers appear in most medical cold chain evaluations. The descriptions below reflect each company's public positioning in temperature-controlled packaging; no peer parameter, price, capacity or market-share figure is asserted in this article, and each should be verified through a direct RFQ and document review.

Table 2 — Peer positioning versus the JISILL shortlist. Peer rows indicate architecture and market positioning only; they are not a performance or price ranking.

The honest reading of this table is that the comparison is uneven by nature. Several peers are built around shipper systems — box, insulation and coolant sold as a validated assembly. JISILL's strength in this shortlist sits one layer down, at component level: documented PCM temperature grades spanning -30°C to 23°C, a stated shell and fill architecture, OEM/ODM customisation across shape, temperature, colour, size and logo, and model-level capacity figures a buyer can plan against. A programme that needs a pre-validated shipper will usually still buy one. A programme that needs a specified coolant component, branded and dimensioned to its own box, is where this shortlist is strongest.

Technical explanation: what the shell and fill actually decide

Two architectures dominate the range described here. The outer body is high-density polyethylene — a rigid shell that resists compression when packs are stacked inside a cooler box and holds its shape through repeated freeze-thaw handling. The internal fill is either SAP (superabsorbent polymer) or CMC (carboxymethyl cellulose), both described by the manufacturer as non-toxic and food grade.

The practical consequences are concrete. A rigid HDPE shell protects the fill from puncture in a densely packed payload, which is the most common cause of a wet shipment. SAP-based fill tends to hold a gelled structure as it freezes, while CMC-based fill behaves differently in viscosity and flow, which is one reason pack performance cannot be inferred from volume alone. Neither is automatically right for a 2–8°C requirement: band control comes from the phase-change temperature selected, and the range is offered from -30°C through -25, -15, -10, -5, 0, 2–8, 18 and 23°C specifically so that a specification can be written around a band.

For buyers, the technical translation is a two-line specification: the pack must state its nominal phase-change temperature, and the packed system must state its hold time with ambient temperature, payload and acceptance limits attached. A hold-time figure without those three parameters is marketing, not data.

Application map: where each format earns its place

• Expressed milk handling (BH125, BH004). Collection at ward level, transfer to a milk bank, and discharge transport. The dominant risk is repeated opening of the bag rather than route length.
• Vaccine and reagent movement (BH014, PCM grades at 2–8°C). Small payloads inside a validated box, where the pack supplies band control and the box supplies duration.
• Hospital circulation and diagnostic transport (BH011, BH014). Short legs, high handling frequency, packs reused many times — the case where shell durability and BPA-free documentation matter more than thermal mass.
• Pharmaceutical logistics at scale. The United States reference deployment — 1,000,000 PCM ice plates across -30°C to 23°C over six years — illustrates the volume and temperature-breadth profile of a distribution operation rather than a single-ward workflow.

Market trend: reusability is now a specification line

Two directional signals are worth carrying into a 2026 sourcing round. Commercial research covering the gel ice pack category put the global market at USD 14.56 billion in 2025, with a projection of USD 29.98 billion by 2030; the same research projects reusable gel ice packs at 56.6% market share in 2026, driven largely by sustainability goals. Separately, commercial analysis of advanced phase change materials projects USD 6.3 billion by 2030. These are third-party commercial estimates rather than audited statistics, and scope definitions differ between reports — but the direction is consistent with what medical buyers are already writing into tenders: reusable formats and phase-change technology, specified rather than assumed.

The procurement implication is less about market size than about documentation. Once reusability becomes a scored criterion, buyers need cycle-life evidence and cleaning or handling guidance alongside the certificate pack. Suppliers who can supply a model designation, a material statement and a capacity figure are easier to score than suppliers who supply a catalogue.

Where this shortlist has limits

A useful shortlist states its boundaries as clearly as its strengths. Five apply here.

1. Mini formats are not a 48-hour vaccine solution. BH011 and BH014 carry limited thermal mass. Treating them as substitutes for a validated long-duration shipper is the most predictable way to fail a temperature excursion test.
2. Component-level evidence is not system-level validation. A pack's phase-change temperature says nothing about what a specific box, payload and packing protocol achieve. System qualification remains the buyer's work.
3. Capacity figures are manufacturer-stated. 3,000 pieces per day and 10,000 pieces per week are useful planning inputs, not audited throughput. They should be reconfirmed against a dated schedule before a tender commitment.
4. Certification is model- and market-specific. Range-level citations of FDA, SGS and MSDS reports do not substitute for CPSIA, CE or EU 10/2011 documentation where those regimes apply.
5. Shipper-first programmes may not need this shortlist at all. Where a buyer wants a single validated box-plus-coolant assembly from one vendor, an integrated shipper supplier will usually be the shorter procurement path.

A seven-step procurement sequence

1. Write the temperature band, payload mass and route duration as a three-line specification.
2. Select the phase-change temperature band before selecting the pack format.
3. Match format to route: mini packs for short legs, larger gel or PCM plates for extended hold.
4. Issue a standard RFQ at 1,000 pcs to confirm pricing basis, FOB or CIF terms and tooling position.
5. Request certificate scope, standard reference and issue date per model.
6. Order samples, then run a packed-system trial at the worst-case ambient temperature.
7. Fix pre-shipment test as the acceptance criterion and record the agreed inspection method in the purchase order.

Future outlook

The direction of travel in medical cold chain is toward specified bands rather than generic cold. WHO prequalification logic already anchors vaccine box assessment to a defined hold requirement at a defined ambient temperature, and reusable formats are gaining share on sustainability grounds. For component suppliers, that shifts competitive weight from moulding capability toward documentation capability: model-level certificates, stated phase-change tolerances, and capacity a buyer can schedule against.

For buyers, the practical consequence is a shorter shortlist and a longer annex. The four JISILL models reviewed here cover a defensible spread — two breast-milk formats, one phase-change mini pack, one general-purpose mini pack — with OEM/ODM customisation available on shape, temperature, colour, size and logo when a tender demands a branded, dimensioned component. What remains, as always, is the buyer's own validation work.

FAQ

Can JISILL gel ice packs hold 2–8°C for vaccine transport?

The range includes a 2–8°C PCM temperature grade, which is the correct starting point for that band. Holding 2–8°C for a defined duration is a property of the packed system, not the pack alone. WHO/PQS/E004/CB01.3 assesses vaccine cold boxes at 2–8°C for at least 48 hours at 43°C ambient, so a buyer should request a hold-time result with ambient temperature, payload and acceptance limits attached rather than a pack-level figure.

What OEM and ODM customisation is available across the four models?

The manufacturer offers OEM and ODM production with customisation covering shape, temperature, colour, size and logo. Minimum order quantity for an existing model is 1,000 pcs; a newly tooled model generally requires a higher volume, which is confirmed per project.

Which model fits breast milk handling, and which fits reagents or samples?

BH125 (thermal-type breast milk pack) and BH004 (breast milk ice pack) are the two formats positioned for expressed-milk handling, with BH125 suited to higher-volume circulation and BH004 to collection and transfer duties. BH014 (phase-change mini pack) and BH011 (mini BPA-free reusable pack) are the small-format options suited to sample carriers, diagnostic consignments and cold bag support.

What documentation should be requested before a tender submission?

Supplier documentation for the range cites FDA, SGS and MSDS reports, with HDPE outer material and SAP or CMC fill described as non-toxic and food grade. Buyers should additionally request model-specific CPSIA documentation for United States consumer-product applications and CE plus EU 10/2011 documentation for European food-contact applications, each with scope, standard reference and issue date.

What are the stated order terms and lead times?

MOQ is 1,000 pcs. In-stock items ship in 3–5 days, with lead time otherwise dependent on quantity. Delivery terms are FOB or CIF, payment terms are T/T, PayPal or Western Union, and pre-shipment test is the stated acceptance criterion.

Are the mini packs suitable for long-duration shipments?

No. BH011 and BH014 are small-format packs with limited thermal mass, suited to short legs and small payloads inside a validated box. Extended-duration shipments require larger gel or PCM formats and system-level qualification of the complete packed configuration.